Comparison Overview

Arch Pharmalabs, Ltd.

VS

Intas Pharmaceuticals

Arch Pharmalabs, Ltd.

"H" Wing, 4th Floor, Tex Centre, Andheri (E), Mumbai, undefined, 400 072, IN
Last Update: 2025-03-05 (UTC)

Founded in 1999,Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres. Arch Pharmalabs works tirelessly to deliver value, innovation and effective supply chain solutions in the spirit of true partnership. Our large family of satisfied customers range from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a Preferred Supplier or Strategic Partner. Arch Pharmalabs received CNBC TV Emerging India 2006 Award as the No.1 Small or Medium Company in the Pharmaceuticals and Chemicals category.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 678
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Intas Pharmaceuticals

Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, undefined, IN
Last Update: 2025-05-06 (UTC)
Between 750 and 799

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 16,979
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Arch Pharmalabs, Ltd.
100%
Compliance Rate
0/4 Standards Verified
Intas Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Arch Pharmalabs, Ltd. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2025.

Incident History — Arch Pharmalabs, Ltd. (X = Date, Y = Severity)

Arch Pharmalabs, Ltd. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Intas Pharmaceuticals (X = Date, Y = Severity)

Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
Incidents

No Incident

https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
Incidents

No Incident

FAQ

Intas Pharmaceuticals company demonstrates a stronger AI Cybersecurity Score compared to Arch Pharmalabs, Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Intas Pharmaceuticals company has disclosed a higher number of cyber incidents compared to Arch Pharmalabs, Ltd. company.

In the current year, Intas Pharmaceuticals company and Arch Pharmalabs, Ltd. company have not reported any cyber incidents.

Neither Intas Pharmaceuticals company nor Arch Pharmalabs, Ltd. company has reported experiencing a ransomware attack publicly.

Neither Intas Pharmaceuticals company nor Arch Pharmalabs, Ltd. company has reported experiencing a data breach publicly.

Neither Intas Pharmaceuticals company nor Arch Pharmalabs, Ltd. company has reported experiencing targeted cyberattacks publicly.

Neither Arch Pharmalabs, Ltd. company nor Intas Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Intas Pharmaceuticals company has more subsidiaries worldwide compared to Arch Pharmalabs, Ltd. company.

Intas Pharmaceuticals company employs more people globally than Arch Pharmalabs, Ltd. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds SOC 2 Type 1 certification.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds SOC 2 Type 2 certification.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds ISO 27001 certification.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds PCI DSS certification.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds HIPAA certification.

Neither Arch Pharmalabs, Ltd. nor Intas Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X